Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04777-z
Abstract: Dear Editor, Venetoclax is an oral drug that is BH3-mimetic and a selective B-cell lymphoma 2 (BCL-2) inhibitor. Inhibition of BCL-2 induces apoptosis in hematological malignancies [1]. Venetoclax has shown activity in patients with acute… read more here.
Keywords: response; therapy related; aml; mds aml ... See more keywords